The differences in the metabolic responses to anti-IL6R response between patients with autoimmune diseases and NSTEMI/STEMI patients are not clear, but could include more use of statins in the MI patients that reduce LDL levels, but may increase Lp(a) levels [95]. The gene discussed is LPA; the disease is autoimmune disease.